Valganciclovir for the prophylaxis and treatment of cytomegalovirus infection in solid organ transplantation

Valganciclovir for the prophylaxis and treatment of cytomegalovirus infection in solid organ transplantation

Erin Wade Ticehurst1, Jennifer Trofe-Clark1,2, Emily Blumberg3, Roy D Bloom21Department of Pharmacy Services, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA; 2Renal Electrolyte and Hypertension Division, Department of Medicine, University of Pennsylvania, Philadelphia, P...

Full description

Bibliographic Details
Main Authors:	Erin Wade Ticehurst, Jennifer Trofe-Clark, Emily Blumberg, et al
Format:	Article
Language:	English
Published:	Dove Medical Press 2010-03-01
Series:	Transplant Research and Risk Management
Online Access:	http://www.dovepress.com/valganciclovir-for-the-prophylaxis-and-treatment-of-cytomegalovirus-in-a4170

Similar Items

Efficacy of Low Dose Valganciclovir Prophylaxis for Cytomegalovirus Infection in Kidney Transplantation
by: Ümit Özçelik, et al.
Published: (2020-01-01)

Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients
by: Doesch AO, et al.
Published: (2012-10-01)

Letermovir for Cytomegalovirus Prophylaxis in Lung Transplant Patients with Valganciclovir-Induced Leukopenia
by: Arindam Singha, et al.
Published: (2021-04-01)

Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients
by: A Jayaprakash Patil, et al.
Published: (2010-03-01)

Efficacy of valganciclovir and ganciclovir for cytomegalovirus disease in solid organ transplants: A meta-analysis
by: Siavash Vaziri, et al.
Published: (2014-01-01)

The pharmacokinetics of valganciclovir prophylaxis in pediatric solid organ transplant patients at risk for Epstein&ndash;Barr virus disease
by: Heather&nbsp;E Vezina, et al.
Published: (2009-12-01)

Prophylaxis of Cytomegalovirus Infection in Solid Organ Transplantation, Retrospective Evaluation
by: Albekairy AM, et al.
Published: (2022-06-01)

Detection of Ganciclovir-Resistant Cytomegalovirus in a Prospective Cohort of Kidney Transplant Recipients Receiving Subtherapeutic Valganciclovir Prophylaxis
by: Diana D. Wong, et al.
Published: (2022-06-01)

Cytomegalovirus prophylaxis using low-dose valganciclovir in patients with acute leukemia undergoing allogeneic hematopoietic stem-cell transplantation
by: Po-Hsien Li, et al.
Published: (2021-03-01)

Onset of valganciclovir resistance in two infants with congenital cytomegalovirus infection
by: Francesca Garofoli, et al.
Published: (2020-09-01)

Effectiveness of Valganciclovir 900mg Versus 450mg for Cytomegalovirus Prophylaxis in Renal Transplantation: A Systematic Review and Meta-Analysis
by: wang xin, et al.
Published: (2017-07-01)

Efficacy of short term valganciclovir in a standard-dose for cytomegalovirus prophylaxis in living donor kidney transplantation: a single-center report
by: Gokhan Ertugrul, et al.
Published: (2019-09-01)

Evaluation of alternate-day valganciclovir prophylaxis for cytomegalovirus disease prevention in moderate risk renal transplant patients: A retrospective observational study
by: Puneet Bhuwania, et al.
Published: (2021-01-01)

Refractory ulcerative colitis complicated by cytomegalovirus infection successfully treated with valganciclovir
by: Tiziana Larussa, et al.
Published: (2012-11-01)

Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients.
by: Jong Man Kim, et al.
Published: (2015-01-01)

Valganciclovir for cytomegalovirus preemptive therapy in patients following allogeneic hematopoietic stem cell transplantation
by: LU Xuan, et al.
Published: (2020-09-01)

Role of oral valganciclovir in sick preterm with cytomegalovirus virus infection and ventilation dependence
by: Anumodan Gupta, et al.
Published: (2019-01-01)

Cytomegalovirus retinitis treated with valganciclovir in Wegener&rsquo;s granulomatosis
by: Kabata Y, et al.
Published: (2012-03-01)

Correlation of cytomegalovirus viral load between whole blood and plasma of congenital cytomegalovirus infection under valganciclovir treatment
by: Yuka Torii, et al.
Published: (2023-01-01)

Long-term results of oral valganciclovir for treatment of anterior segment inflammation secondary to cytomegalovirus infection
by: Wong VW, et al.
Published: (2012-04-01)

Efficacy and safety of universal valganciclovir prophylaxis combined with a tacrolimus/mycophenolate-based regimen in kidney transplantation
by: O Manuel, et al.
Published: (2007-12-01)

Prevention and treatment of cytomegalovirus infections in solid organ transplantation
by: Janez Tomažič
Published: (2011-04-01)

A succinct synthesis of valganciclovir hydrochloride – A cytomegalovirus (CMV) retinitis inhibitor
by: Karrothu Srihari Babu
Published: (2011-01-01)

Valganciclovir is not associated with decreased EBV infection rate in pediatric kidney transplantation
by: Elodie Cheyssac, et al.
Published: (2023-01-01)

Less renal allograft fibrosis with valganciclovir prophylaxis for cytomegalovirus compared to high-dose valacyclovir: a parallel group, open-label, randomized controlled trial
by: Tomas Reischig, et al.
Published: (2018-11-01)

Laboratory diagnostic testing for cytomegalovirus infection in solid organ transplant patients
by: Hyeyoung Lee, et al.
Published: (2022-03-01)

Treatment of cytomegalovirus anterior segment infection with intravitreal injection of ganciclovir in adjunction with or without oral valganciclovir: a long-term results
by: Yu-Chun Cheng, et al.
Published: (2021-02-01)

Antifungal Prophylaxis in Solid Organ Transplant Recipients
by: Şebnem ŞENOL, et al.
Published: (2015-12-01)

Treatment of unilateral zone I cytomegalovirus retinitis in acute lymphoblastic leukemia with oral valganciclovir and intravitreal ganciclovir
by: Koushik Tripathy, et al.
Published: (2017-01-01)

Effectiveness of valacyclovir prophylaxis against the occurrence of cytomegalovirus infection in kidney transplant recipients
by: Woo Yeong Park, et al.
Published: (2020-03-01)

Non-healing vulval ulcer in an immunocompromised female due to concurrent Herpes Simplex Virus and Cytomegalovirus co-infection treated effectively with Valganciclovir
by: Preema Sinha, et al.
Published: (2020-01-01)

Efficacy and safety of letermovir prophylaxis for cytomegalovirus infection after hematopoietic stem cell transplantation
by: Wen-Wen Li, et al.
Published: (2024-01-01)

Genotyping clinical cytomegalovirus isolates in solid-organs-transplant recipients
by: O. E. Vankova, et al.
Published: (2022-01-01)

Immune Prophylaxis and Therapy for Human Cytomegalovirus Infection
by: Evi B. Struble, et al.
Published: (2021-08-01)

Adoptive Immunotherapy for Prophylaxis and Treatment of Cytomegalovirus Infection
by: Christopher P. Ouellette
Published: (2022-10-01)

A single-centre observational study comparing the impact of different cytomegalovirus prophylaxis strategies on cytomegalovirus infections in kidney transplant recipients
by: Mabel Si Hua Tan, et al.
Published: (2021-06-01)

A Novel Case of CMV Resistance to Valganciclovir and Maribavir in a Renal Transplant Patient
by: Helen Pearce, et al.
Published: (2024-01-01)

Role of Valganciclovir in Children with Congenital CMV Infection: A Review of the Literature
by: Davide Pata, et al.
Published: (2023-07-01)

Adequacy of infective endocarditis prophylaxis before dental procedures among solid organ transplant recipients
by: Emir Karacaglar, et al.
Published: (2019-01-01)

Valganciclovir as Add-On to Standard Therapy in Secondary Glioblastoma
by: Giuseppe Stragliotto, et al.
Published: (2020-09-01)